Hemoperfusion Sales Market REPORT OVERVIEW
-
Request a Free Sample to learn more about this report
The global Hemoperfusion Sales market size was USD 501 million in 2021 and market is projected to touch USD 974.6 million by 2032, exhibiting a CAGR of 18.1% during the forecast period.
The global COVID-19 pandemic has been unprecedented and staggering, with the hemoperfusion sales market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the market's growth and demand returning to pre-pandemic levels once the pandemic is over.
Hemoperfusion is a medical procedure that is used to remove toxins or harmful substances from the bloodstream. The procedure involves passing the patient's blood through a device that contains an adsorbent material, which can adsorb the toxins or harmful substances. The adsorbent material used in hemoperfusion can vary depending on the type of toxins or substances that need to be removed.
The procedure involves the insertion of a catheter into a large vein, typically in the groin or neck area. The blood is then pumped through the hemoperfusion device, which contains the adsorbent material. The purified blood is then returned to the patient's body through another catheter. Hemoperfusion is most commonly used in cases of acute poisoning or drug overdose, where the patient has ingested a toxic substance that cannot be effectively removed by other means.
COVID-19 Impact: Shortage in Supply Hampered Market Demand.
COVID-19 had a life changing impact globally. The global hemoperfusion sales market share was significantly affected. The virus had various impacts on different markets. Lockdowns were imposed in several nations. This erratic pandemic caused disruptions on all sorts of businesses. Restrictions tightened during the pandemic due to increasing number of cases. Numerous Industries were affected. However, the market for hemoperfusion sales experienced an increased demand.
The pandemic has also had some negative impacts on the availability of hemoperfusion devices and supplies. The increased demand for these devices has led to shortages in some areas, particularly in regions that have been hit hardest by the pandemic. This has led to delays and shortages of some products, which has impacted the ability of healthcare providers to offer hemoperfusion as a treatment option.
One of the effects of the pandemic has been an increase in the number of critically ill patients, including those with severe cases of COVID-19. Hemoperfusion has been used as a treatment option for some COVID-19 patients, particularly those with severe respiratory symptoms or those with acute kidney injury caused by the virus. The market is anticipated to boost the global hemoperfusion sales market share following the pandemic.
LATEST TRENDS
"Integration in Multiple Treatments to Benefit Market Prospects"
One notable development is the use of hemoperfusion in sepsis treatment. Sepsis is a life-threatening condition that can result from an infection, and hemoperfusion has been shown to effectively remove endotoxins from the bloodstream in septic patients. This has led to increased interest in the use of hemoperfusion as a treatment option for sepsis.
Advancements in the technology used in hemoperfusion devices have also been made, including the use of new adsorbent materials that can target specific toxins or substances in the bloodstream. This has led to more targeted and effective toxin removal and improved patient outcomes. In addition, there is ongoing research into the effectiveness of hemoperfusion in various applications which is anticipated to boost the global hemoperfusion sales market growth.
Hemoperfusion Sales Market SEGMENTATION
-
Request a Free Sample to learn more about this report
- By Type
Based on type, the market is divided into Activated Carbon Adsorption, and Resin Adsorption.
- By Application
Based on application, the market is bifurcated into Hepatic Encephalopathy, Certain Autoimmune Diseases, Drug Overdose, Specific Intoxications, and Others.
DRIVING FACTORS
"Increasing Rate of Drug Overdose to Increase Market Demand"
Hemoperfusion is a particularly effective treatment for patients who have ingested a toxic substance that cannot be effectively removed by other means. This makes it a critical treatment option for cases of acute poisoning or drug overdose. The increasing incidence of drug overdose and poisoning cases, particularly opioid overdose, has led to increased interest in the use of hemoperfusion as a treatment option.
"Technological Exposure to Increase Market Share"
Advancements in the technology used in hemoperfusion devices, including the use of new adsorbent materials and improved device design, have made the treatment more effective and accessible to patients. Hemoperfusion can also be used in cases where patients have been exposed to environmental or industrial toxins, such as heavy metals or pesticides. These factors are expected to drive the global hemoperfusion sales market share.
RESTRAINING FACTORS
"Lack of Expertise to Hamper Market Share"
Hemoperfusion requires specialized training and expertise to administer and monitor, and may not be available at all healthcare facilities or by all healthcare providers. This can limit its use as a treatment option and may result in delays in treatment for patients who need it. Hemoperfusion can carry some risks and potential complications, such as bleeding, infection, or damage to the red blood cells. These risks need to be carefully monitored and managed by trained healthcare professionals. Hence these factors could hamper the global hemoperfusion sales market share.
Hemoperfusion Sales Market REGIONAL INSIGHTS
-
Request a Free Sample to learn more about this report
"Asia Pacific Dominates the Hemoperfusion Sales Market"
APAC is the major shareholder for the global hemoperfusion sales market share. This is driven by increasing healthcare spending, rising incidence of acute poisonings and drug overdose, and growing awareness of the benefits of hemoperfusion as a treatment option. North America is anticipated to boost the global hemoperfusion sales market share.
KEY INDUSTRY PLAYERS
"Market Players Focus on New Product Launches to Strengthen Market Position"
Leading players in the market are adopting various strategies to expand their presence in the market. These include R&D investments and launch of new, technologically-advanced products in the market. Some companies are also adopting strategies such as partnerships, mergers, and acquisitions to strengthen their market position.
List of Market Players Profiled
- Jafron Biomedical Co [China]
- Baxter International [U.S.]
- Asahi-Kasei [Japan]
- Biosun Medical [India]
- Kaneka Corporation [Japan]
- Toray Industries [Japan]
- Cytosorbents Corporation [U.S.]
- American Institute for Economic Research [U.S.]
- Zibo Kangbei [China]
REPORT COVERAGE
This research profiles a report with extensive studies that take into description of the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, restraints, etc. This analysis is subject to alteration if the key players and probable analysis of market dynamics changes.
REPORT COVERAGE | DETAILS |
---|---|
Market Size Value In |
US$ 501 Million in 2021 |
Market Size Value By |
US$ 974.6 Million by 2032 |
Growth Rate |
CAGR of 18.1% from 2021 to 2032 |
Forecast Period |
2024-2032 |
Base Year |
2023 |
Historical Data Available |
Yes |
Regional Scope |
Global |
Segments Covered |
Type and Application |
Frequently Asked Questions
-
Which region dominates the global hemoperfusion sales market?
Asia Pacific dominates the global hemoperfusion sales market.
-
Which are the driving factors of the hemoperfusion sales market?
Increasing Rate of Drug Overdose and Technological Exposure are the driving factors of the hemoperfusion sales market.
-
Which are the top companies operating in the hemoperfusion sales market?
Jafron Biomedical Co, Baxter International, Asahi-Kasei, Biosun Medical, Kaneka Corporation, Toray Industries, Cytosorbents Corporation, American Institute for Economic Research, and Zibo Kangbei are key companies operating in the hemoperfusion sales market.